Evaluating Anti-TNF-Alpha Therapy in Patients with Relapsed and Refractory Langerhans Cell Histiocytosis

Conclusion: Etanercept therapy, at JRA-effective dose, in this trial did not improve LCH disease. It is possible that this may not be an effective strategy. Alternatively, it is also possible that drug dose or distribution was suboptimal. While anti-TNF therapies, including etanercept, are effective for treatment of RA, etanercept is not effective for granulomatous diseases such as Crohn's, sarcoidosis or Wegner's disease. Additional studies exploring potential efficacy of higher dose or alternative forms of TNF-alpha inhibition in LCH may be warranted.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Burke, T., Legarreta, A., Lin, H., Scull, B., Eckstein, O. S., McClain, K. L., Allen, C. E. Tags: 201. Granulocytes, Monocytes, and Macrophages Source Type: research